Don't Judge Morphic on Technicals Alone - Check Its Fundamentals!

By Scott Lee • Friday, May 05 09:45 • Permanent Link

Small-cap Health Care company Morphic has moved 0.6% so far today on a volume of 96,436, compared to its average of 576,287. In contrast, the S&P 500 index moved 1.0%.

Morphic trades -28.09% away from its average analyst target price of $73.88 per share. The 8 analysts following the stock have set target prices ranging from $60.0 to $106.0, and on average have given Morphic a rating of buy.

Anyone interested in buying MORF should be aware of the facts below:

Morphic has moved 79.3% over the last year, and the S&P 500 logged a change of -1.5%
Based on its trailing earnings per share of -1.74, Morphic has a trailing 12 month Price to Earnings (P/E) ratio of -30.5 while the S&P 500 average is 15.97
MORF has a forward P/E ratio of -13.3 based on its forward 12 month price to earnings (EPS) of $-4.0 per share
Its Price to Book (P/B) ratio is 4.94 compared to its sector average of 4.16
Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, and metabolic diseases, as well as fibrosis and cancer.
Based in Waltham, the company has 107 full time employees and a market cap of $2.11 Billion.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.